These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 12973166

  • 1. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia.
    Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, Allaouchiche B.
    Crit Care Med; 2003 Aug; 31(8):2102-6. PubMed ID: 12973166
    [Abstract] [Full Text] [Related]

  • 2. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia.
    Boselli E, Breilh D, Rimmelé T, Poupelin JC, Saux MC, Chassard D, Allaouchiche B.
    Intensive Care Med; 2004 May; 30(5):989-91. PubMed ID: 14985960
    [Abstract] [Full Text] [Related]

  • 3. Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia.
    Jaruratanasirikul S, Sriwiriyajan S, Ingviya N.
    J Pharm Pharmacol; 2002 Dec; 54(12):1693-6. PubMed ID: 12542901
    [Abstract] [Full Text] [Related]

  • 4. [Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia].
    Cousson J, Floch T, Vernet-Garnier V, Appriou M, Petit JS, Jovenin N, Lamiable D, Hoizey G.
    Pathol Biol (Paris); 2005 Dec; 53(8-9):546-50. PubMed ID: 16023303
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia.
    Boselli E, Breilh D, Cannesson M, Xuereb F, Rimmelé T, Chassard D, Saux MC, Allaouchiche B.
    Intensive Care Med; 2004 May; 30(5):976-9. PubMed ID: 15057512
    [Abstract] [Full Text] [Related]

  • 7. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
    Isla A, Gascón AR, Maynar J, Arzuaga A, Toral D, Pedraz JL.
    Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
    [Abstract] [Full Text] [Related]

  • 8. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia.
    Boselli E, Breilh D, Rimmelé T, Guillaume C, Xuereb F, Saux MC, Bouvet L, Chassard D, Allaouchiche B.
    Crit Care Med; 2008 May; 36(5):1500-6. PubMed ID: 18434883
    [Abstract] [Full Text] [Related]

  • 9. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
    Lorente L, Jiménez A, Palmero S, Jiménez JJ, Iribarren JL, Santana M, Martín MM, Mora ML.
    Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Population pharmacokinetics of cefepime in neonates with severe nosocomial infections.
    Lima-Rogel V, Medina-Rojas EL, Del Carmen Milán-Segovia R, Noyola DE, Nieto-Aguirre K, López-Delarosa A, Romano-Moreno S.
    J Clin Pharm Ther; 2008 Jun; 33(3):295-306. PubMed ID: 18452417
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF, Bulitta J, Lipman J, Kirkpatrick CM.
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD, Droege CA, Droege ME, Healy DP, Courter JD, Ernst NE, Harger NJ, Foertsch MJ, Winter JB, Carter KE, Van Fleet SL, Athota K, Mueller EW.
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia.
    Boselli E, Breilh D, Rimmelé T, Djabarouti S, Saux MC, Chassard D, Allaouchiche B.
    Crit Care Med; 2005 Jan; 33(1):104-9. PubMed ID: 15644655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.